Article Text

Download PDFPDF
E-054 initial procedural outcomes in 20 consecutive pipeline flex cases: the first american series
  1. G Colby1,
  2. L Lin2,
  3. J Caplan1,
  4. B Jiang1,
  5. J Huang1,
  6. R Tamargo1,
  7. A Coon1
  1. 1Neurosurgery, Johns Hopkins, Baltimore, MD, USA
  2. 2Neurosurgery, University of California, Irvine, Orange, CA, USA


Background Flow diversion is an effective and increasingly accepted method for the endovascular treatment of cerebral aneurysms. The Pipeline FLEX Embolization Device (PED FLEX) is a second-generation flow diverter recently approved in the United States. We report our initial experience of 20 cases with this device.

Methods Twenty consecutive patients with intracranial aneurysms amenable to flow diversion were treated with the PED FLEX. Data were collected for patient demographics, aneurysms characteristics, technical procedural details, and length of post-procedure hospital stay.

Results Twenty patients (mean age 56.1 ± 3.6 years; range 29 to 81 years) with 20 unruptured aneurysms (mean size 6.4 ± 0.9 mm; range 2.7 to 15 mm) were treated. For proximal access, 8/20 cases (40%) had significant cervical ICA tortuosity, and 12/20 (60%) had cavernous ICA ≥ grade II. The PED FLEX was implanted in 100% of cases. A single device was used in 19/20 (95%) cases, and 3 devices were used in one case. Post-processing balloon angioplasty was performed 6/20 (30%) of cases. Re-sheathing was only used in 1 case for device re-positioning. Complete aneurysm neck coverage and adequate vessel wall apposition was obtained in all 20 cases. No periprocedural stroke or hemorrhage was observed. Mean post-procedure hospital stay was 1.3 ± 0.1 days, with 15/20 (75%) of patients being discharged on post-procedure day 1.

Conclusions Pipeline FLEX is a second-generation flow diverter with unique delivery-specific features compared to the traditional Pipeline. Our initial experience in 20 cases demonstrates a favorable technical and clinical profile for the treatment of intracranial aneurysms.

Disclosures G. Colby: 2; C; Covidien, Microvention. L. Lin: None. J. Caplan: None. B. Jiang: None. J. Huang: None. R. Tamargo: None. A. Coon: 2; C; Covidien, Stryker, Microvention.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.